Can Pemetinib/Dabotan be used to treat kidney disease?

Pemigatinib (Pemigatinib) is a small molecule JAK/FGFR inhibitor, mainly used to treat advanced cholangiocarcinoma (CCA) and myeloid/lymphoid tumors with FGFR1 rearrangement. Many patients or family members will be concerned about one question: whether pemetinib can also be used to treat kidney disease. According to official guidelines and drug inserts, the indications of pemetinib are clearly targeted at cancer patients, especially those with cholangiocarcinoma carrying FGFR2 fusions or rearrangements, and patients with myeloid/lymphoid tumors associated with FGFR1 rearrangements. To date, there is no reliable clinical evidence that pemetinib can be used in renal diseases, including chronic kidney disease or other non-neoplastic renal dysfunction. Therefore, pemetinib is not an appropriate treatment option for patients with renal disease.

In the treatment of cholangiocarcinoma, pemetinib is mainly used for patients with previously failed treatment, unresectable or metastatic cholangiocarcinoma. By selectively inhibiting the FGFR2 signaling pathway, it can block molecular pathways related to tumor cell proliferation and metastasis, improving disease control and quality of life. In patients with myeloid/lymphoid tumors associated with FGFR1 rearrangement, pemetinib also inhibits the growth of malignant cells by interfering with abnormal FGFR1 signaling, achieving long-term management of relapsed or refractory tumors. Both indications emphasize the importance of molecular classification, and precise targeting makes the drug efficacy significantly better than non-specific chemotherapy.

Although pemetinib has shown unique efficacy in the field of cancer, there is currently no relevant clinical research support for kidney disease or other non-tumor diseases. Patients should avoid using it on their own or trying to expand the indications to avoid unnecessary risks or side effects. For non-neoplastic renal disease, existing guidelines and standard treatment regimens should be followed, and pemetinib should still be used strictly in accordance with the approved indications.

Reference materials:https://go.drugbank.com/drugs/DB15102